Contemporary	O
use	O
of	O
ticagrelor	B:C1999375
in	O
patients	O
with	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
:	O
insights	O
from	O
Swedish	O
Web	I:C0282574
System	I:C0282574
for	I:C0282574
Enhancement	I:C0282574
and	I:C0282574
Development	I:C0282574
of	I:C0282574
Evidence	I:C0282574
-	I:C0282574
Based	I:C0282574
Care	I:C0282574
in	I:C0282574
Heart	I:C0282574
Disease	I:C0282574
Evaluated	I:C0282574
According	I:C0282574
to	I:C0282574
Recommended	I:C0282574
Therapies	I:C0282574
(	I:C0282574
SWEDEHEART	I:C0282574
)	I:C0282574
.	O

Contemporary	O
use	O
of	O
ticagrelor	O
in	O
patients	O
with	O
acute	B:C0948089
coronary	I:C0948089
syndrome	I:C0948089
:	O
insights	O
from	O
Swedish	O
Web	I:C0282574
System	I:C0282574
for	I:C0282574
Enhancement	I:C0282574
and	I:C0282574
Development	I:C0282574
of	I:C0282574
Evidence	I:C0282574
-	I:C0282574
Based	I:C0282574
Care	I:C0282574
in	I:C0282574
Heart	I:C0282574
Disease	I:C0282574
Evaluated	I:C0282574
According	I:C0282574
to	I:C0282574
Recommended	I:C0282574
Therapies	I:C0282574
(	I:C0282574
SWEDEHEART	I:C0282574
)	I:C0282574
.	O

Contemporary	O
use	O
of	O
ticagrelor	O
in	O
patients	O
with	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
:	O
insights	O
from	O
Swedish	B:C0282574
Web	I:C0282574
System	I:C0282574
for	I:C0282574
Enhancement	I:C0282574
and	I:C0282574
Development	I:C0282574
of	I:C0282574
Evidence	I:C0282574
-	I:C0282574
Based	I:C0282574
Care	I:C0282574
in	I:C0282574
Heart	I:C0282574
Disease	I:C0282574
Evaluated	I:C0282574
According	I:C0282574
to	I:C0282574
Recommended	I:C0282574
Therapies	I:C0282574
(	I:C0282574
SWEDEHEART	I:C0282574
)	I:C0282574
.	O

The	O
platelet	B:C0032188
inhibitor	I:C0032188
ticagrelor	O
is	O
strongly	O
recommended	O
during	O
12	O
months	O
post	O
-	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
(	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
)	O
in	O
European	O
guidelines	O
.	O

The	O
platelet	O
inhibitor	I:C0032188
ticagrelor	B:C1999375
is	O
strongly	O
recommended	O
during	O
12	O
months	O
post	O
-	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
(	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
)	O
in	O
European	O
guidelines	O
.	O

The	O
platelet	O
inhibitor	I:C0032188
ticagrelor	O
is	O
strongly	O
recommended	O
during	O
12	O
months	O
post	O
-	O
acute	B:C0948089
coronary	I:C0948089
syndrome	I:C0948089
(	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
)	O
in	O
European	O
guidelines	O
.	O

The	O
platelet	O
inhibitor	I:C0032188
ticagrelor	O
is	O
strongly	O
recommended	O
during	O
12	O
months	O
post	O
-	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
(	O
acute	B:C0948089
coronary	I:C0948089
syndrome	I:C0948089
)	O
in	O
European	O
guidelines	O
.	O

The	O
platelet	O
inhibitor	I:C0032188
ticagrelor	O
is	O
strongly	O
recommended	O
during	O
12	O
months	O
post	O
-	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
(	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
)	O
in	O
European	B:C0015176
guidelines	O
.	O

The	O
platelet	O
inhibitor	I:C0032188
ticagrelor	O
is	O
strongly	O
recommended	O
during	O
12	O
months	O
post	O
-	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
(	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
)	O
in	O
European	O
guidelines	B:C0162791
.	O

We	O
analysed	B:C0936012
clinical	O
characteristics	O
of	O
patients	O
given	O
ticagrelor	O
for	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
in	O
the	O
real	O
world	O
.	O

We	O
analysed	O
clinical	O
characteristics	O
of	O
patients	O
given	O
ticagrelor	B:C1999375
for	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
in	O
the	O
real	O
world	O
.	O

We	O
analysed	O
clinical	O
characteristics	O
of	O
patients	O
given	O
ticagrelor	O
for	O
acute	B:C0948089
coronary	I:C0948089
syndrome	I:C0948089
in	O
the	O
real	O
world	O
.	O

We	O
studied	B:C2603343
the	O
use	O
of	O
ticagrelor	O
in	O
patients	O
admitted	O
for	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
in	O
Sweden	O
between	O
1	O
January	O
2012	O
and	O
31	O
December	O
2013	O
who	O
were	O
enrolled	O
in	O
the	O
Swedish	O
Web	I:C0282574
system	I:C0282574
for	I:C0282574
Enhancement	I:C0282574
and	I:C0282574
Development	I:C0282574
of	I:C0282574
Evidence	I:C0282574
-	I:C0282574
based	I:C0282574
care	I:C0282574
in	I:C0282574
Heart	I:C0282574
disease	I:C0282574
Evaluated	I:C0282574
According	I:C0282574
to	I:C0282574
Recommended	I:C0282574
Therapies	I:C0282574
(	I:C0282574
SWEDEHEART	I:C0282574
)	I:C0282574
.	O

We	O
studied	O
the	O
use	O
of	O
ticagrelor	B:C1999375
in	O
patients	O
admitted	O
for	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
in	O
Sweden	O
between	O
1	O
January	O
2012	O
and	O
31	O
December	O
2013	O
who	O
were	O
enrolled	O
in	O
the	O
Swedish	O
Web	I:C0282574
system	I:C0282574
for	I:C0282574
Enhancement	I:C0282574
and	I:C0282574
Development	I:C0282574
of	I:C0282574
Evidence	I:C0282574
-	I:C0282574
based	I:C0282574
care	I:C0282574
in	I:C0282574
Heart	I:C0282574
disease	I:C0282574
Evaluated	I:C0282574
According	I:C0282574
to	I:C0282574
Recommended	I:C0282574
Therapies	I:C0282574
(	I:C0282574
SWEDEHEART	I:C0282574
)	I:C0282574
.	O

We	O
studied	O
the	O
use	O
of	O
ticagrelor	O
in	O
patients	O
admitted	B:C0184666
for	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
in	O
Sweden	O
between	O
1	O
January	O
2012	O
and	O
31	O
December	O
2013	O
who	O
were	O
enrolled	O
in	O
the	O
Swedish	O
Web	I:C0282574
system	I:C0282574
for	I:C0282574
Enhancement	I:C0282574
and	I:C0282574
Development	I:C0282574
of	I:C0282574
Evidence	I:C0282574
-	I:C0282574
based	I:C0282574
care	I:C0282574
in	I:C0282574
Heart	I:C0282574
disease	I:C0282574
Evaluated	I:C0282574
According	I:C0282574
to	I:C0282574
Recommended	I:C0282574
Therapies	I:C0282574
(	I:C0282574
SWEDEHEART	I:C0282574
)	I:C0282574
.	O

We	O
studied	O
the	O
use	O
of	O
ticagrelor	O
in	O
patients	O
admitted	O
for	O
acute	B:C0948089
coronary	I:C0948089
syndrome	I:C0948089
in	O
Sweden	O
between	O
1	O
January	O
2012	O
and	O
31	O
December	O
2013	O
who	O
were	O
enrolled	O
in	O
the	O
Swedish	O
Web	I:C0282574
system	I:C0282574
for	I:C0282574
Enhancement	I:C0282574
and	I:C0282574
Development	I:C0282574
of	I:C0282574
Evidence	I:C0282574
-	I:C0282574
based	I:C0282574
care	I:C0282574
in	I:C0282574
Heart	I:C0282574
disease	I:C0282574
Evaluated	I:C0282574
According	I:C0282574
to	I:C0282574
Recommended	I:C0282574
Therapies	I:C0282574
(	I:C0282574
SWEDEHEART	I:C0282574
)	I:C0282574
.	O

We	O
studied	O
the	O
use	O
of	O
ticagrelor	O
in	O
patients	O
admitted	O
for	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
in	O
Sweden	B:C0038995
between	O
1	O
January	O
2012	O
and	O
31	O
December	O
2013	O
who	O
were	O
enrolled	O
in	O
the	O
Swedish	O
Web	I:C0282574
system	I:C0282574
for	I:C0282574
Enhancement	I:C0282574
and	I:C0282574
Development	I:C0282574
of	I:C0282574
Evidence	I:C0282574
-	I:C0282574
based	I:C0282574
care	I:C0282574
in	I:C0282574
Heart	I:C0282574
disease	I:C0282574
Evaluated	I:C0282574
According	I:C0282574
to	I:C0282574
Recommended	I:C0282574
Therapies	I:C0282574
(	I:C0282574
SWEDEHEART	I:C0282574
)	I:C0282574
.	O

We	O
studied	O
the	O
use	O
of	O
ticagrelor	O
in	O
patients	O
admitted	O
for	O
acute	O
coronary	I:C0948089
syndrome	I:C0948089
in	O
Sweden	O
between	O
1	O
January	O
2012	O
and	O
31	O
December	O
2013	O
who	O
were	O
enrolled	O
in	O
the	O
Swedish	B:C0282574
Web	I:C0282574
system	I:C0282574
for	I:C0282574
Enhancement	I:C0282574
and	I:C0282574
Development	I:C0282574
of	I:C0282574
Evidence	I:C0282574
-	I:C0282574
based	I:C0282574
care	I:C0282574
in	I:C0282574
Heart	I:C0282574
disease	I:C0282574
Evaluated	I:C0282574
According	I:C0282574
to	I:C0282574
Recommended	I:C0282574
Therapies	I:C0282574
(	I:C0282574
SWEDEHEART	I:C0282574
)	I:C0282574
.	O

Clinical	O
characteristics	O
were	O
investigated	O
for	O
patients	O
prescribed	O
ticagrelor	B:C1999375
at	O
discharge	O
as	O
well	O
as	O
for	O
patients	O
undergoing	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
who	O
were	O
prescribed	O
ticagrelor	O
.	O

Clinical	O
characteristics	O
were	O
investigated	O
for	O
patients	O
prescribed	O
ticagrelor	O
at	O
discharge	B:C0030685
as	O
well	O
as	O
for	O
patients	O
undergoing	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
who	O
were	O
prescribed	O
ticagrelor	O
.	O

Clinical	O
characteristics	O
were	O
investigated	O
for	O
patients	O
prescribed	O
ticagrelor	O
at	O
discharge	O
as	O
well	O
as	O
for	O
patients	O
undergoing	O
percutaneous	B:C1532338
coronary	I:C1532338
intervention	I:C1532338
who	O
were	O
prescribed	O
ticagrelor	O
.	O

Clinical	O
characteristics	O
were	O
investigated	O
for	O
patients	O
prescribed	O
ticagrelor	O
at	O
discharge	O
as	O
well	O
as	O
for	O
patients	O
undergoing	O
percutaneous	O
coronary	I:C1532338
intervention	I:C1532338
who	O
were	O
prescribed	O
ticagrelor	B:C1999375
.	O

Independent	O
factors	O
associated	O
with	O
selecting	O
ticagrelor	B:C1999375
were	O
analysed	O
in	O
logistic	O
regression	I:C0206031
.	O

Independent	O
factors	O
associated	O
with	O
selecting	O
ticagrelor	O
were	O
analysed	B:C0936012
in	O
logistic	O
regression	I:C0206031
.	O

Independent	O
factors	O
associated	O
with	O
selecting	O
ticagrelor	O
were	O
analysed	O
in	O
logistic	B:C0206031
regression	I:C0206031
.	O

We	O
found	O
that	O
44.0	O
%	O
(	O
n	O
=	O
12	O
601	O
)	O
out	O
of	O
a	O
total	O
of	O
28	O
639	O
patients	O
had	O
been	O
prescribed	O
ticagrelor	B:C1999375
at	O
discharge	O
.	O

We	O
found	O
that	O
44.0	O
%	O
(	O
n	O
=	O
12	O
601	O
)	O
out	O
of	O
a	O
total	O
of	O
28	O
639	O
patients	O
had	O
been	O
prescribed	O
ticagrelor	O
at	O
discharge	B:C0030685
.	O

After	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
prior	O
cardiovascular	B:C0007222
disease	I:C0007222
was	O
less	O
common	I:C0243095
in	O
patients	O
discharged	O
on	O
ticagrelor	O
(	O
myocardial	O
infarction	I:C0027051
,	O
ischaemic	O
stroke	I:C0948008
,	O
and	O
peripheral	O
vascular	I:C0085096
disease	I:C0085096
;	O
P	O
for	O
all	O
<	O
0.001	O
)	O
.	O

After	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
prior	O
cardiovascular	O
disease	I:C0007222
was	O
less	B:C0243095
common	I:C0243095
in	O
patients	O
discharged	O
on	O
ticagrelor	O
(	O
myocardial	O
infarction	I:C0027051
,	O
ischaemic	O
stroke	I:C0948008
,	O
and	O
peripheral	O
vascular	I:C0085096
disease	I:C0085096
;	O
P	O
for	O
all	O
<	O
0.001	O
)	O
.	O

After	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
prior	O
cardiovascular	O
disease	I:C0007222
was	O
less	O
common	I:C0243095
in	O
patients	O
discharged	B:C0030685
on	O
ticagrelor	O
(	O
myocardial	O
infarction	I:C0027051
,	O
ischaemic	O
stroke	I:C0948008
,	O
and	O
peripheral	O
vascular	I:C0085096
disease	I:C0085096
;	O
P	O
for	O
all	O
<	O
0.001	O
)	O
.	O

After	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
prior	O
cardiovascular	O
disease	I:C0007222
was	O
less	O
common	I:C0243095
in	O
patients	O
discharged	O
on	O
ticagrelor	B:C1999375
(	O
myocardial	O
infarction	I:C0027051
,	O
ischaemic	O
stroke	I:C0948008
,	O
and	O
peripheral	O
vascular	I:C0085096
disease	I:C0085096
;	O
P	O
for	O
all	O
<	O
0.001	O
)	O
.	O

After	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
prior	O
cardiovascular	O
disease	I:C0007222
was	O
less	O
common	I:C0243095
in	O
patients	O
discharged	O
on	O
ticagrelor	O
(	O
myocardial	B:C0027051
infarction	I:C0027051
,	O
ischaemic	O
stroke	I:C0948008
,	O
and	O
peripheral	O
vascular	I:C0085096
disease	I:C0085096
;	O
P	O
for	O
all	O
<	O
0.001	O
)	O
.	O

After	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
prior	O
cardiovascular	O
disease	I:C0007222
was	O
less	O
common	I:C0243095
in	O
patients	O
discharged	O
on	O
ticagrelor	O
(	O
myocardial	O
infarction	I:C0027051
,	O
ischaemic	B:C0948008
stroke	I:C0948008
,	O
and	O
peripheral	O
vascular	I:C0085096
disease	I:C0085096
;	O
P	O
for	O
all	O
<	O
0.001	O
)	O
.	O

After	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
prior	O
cardiovascular	O
disease	I:C0007222
was	O
less	O
common	I:C0243095
in	O
patients	O
discharged	O
on	O
ticagrelor	O
(	O
myocardial	O
infarction	I:C0027051
,	O
ischaemic	O
stroke	I:C0948008
,	O
and	O
peripheral	B:C0085096
vascular	I:C0085096
disease	I:C0085096
;	O
P	O
for	O
all	O
<	O
0.001	O
)	O
.	O

The	O
risk	B:C0243095
of	I:C0243095
death	I:C0243095
as	O
predicted	O
by	O
GRACE	O
score	O
and	O
the	O
risk	O
of	O
major	O
bleeding	I:C0019080
as	O
predicted	O
by	O
CRUSADE	O
score	O
were	O
both	O
lower	O
in	O
ticagrelor	O
-	O
treated	O
patients	O
vs.	O
others	O
(	O
median	O
99	O
vs.	O
126	O
and	O
median	O
23	O
vs.	O
25	O
,	O
respectively	O
;	O
P	O
for	O
both	O
<	O
0.001	O
)	O
.	O

The	O
risk	O
of	I:C0243095
death	I:C0243095
as	O
predicted	O
by	O
GRACE	O
score	O
and	O
the	O
risk	O
of	O
major	B:C0019080
bleeding	I:C0019080
as	O
predicted	O
by	O
CRUSADE	O
score	O
were	O
both	O
lower	O
in	O
ticagrelor	O
-	O
treated	O
patients	O
vs.	O
others	O
(	O
median	O
99	O
vs.	O
126	O
and	O
median	O
23	O
vs.	O
25	O
,	O
respectively	O
;	O
P	O
for	O
both	O
<	O
0.001	O
)	O
.	O

The	O
risk	O
of	I:C0243095
death	I:C0243095
as	O
predicted	O
by	O
GRACE	O
score	O
and	O
the	O
risk	O
of	O
major	O
bleeding	I:C0019080
as	O
predicted	O
by	O
CRUSADE	O
score	O
were	O
both	O
lower	O
in	O
ticagrelor	B:C1999375
-	O
treated	O
patients	O
vs.	O
others	O
(	O
median	O
99	O
vs.	O
126	O
and	O
median	O
23	O
vs.	O
25	O
,	O
respectively	O
;	O
P	O
for	O
both	O
<	O
0.001	O
)	O
.	O

The	O
intended	O
treatment	O
duration	O
at	O
discharge	B:C0030685
was	O
12	O
months	O
in	O
82.5	O
%	O
of	O
patients	O
and	O
<	O
12	O
months	O
in	O
9.3	O
%	O
.	O

Ticagrelor	B:C1999375
is	O
preferentially	O
being	O
used	O
in	O
patients	O
at	O
lower	O
risk	O
.	O

A	O
minority	B:C0026192
of	O
patients	O
are	O
recommended	O
ticagrelor	O
during	O
<	O
12	O
months	O
.	O

A	O
minority	O
of	O
patients	O
are	O
recommended	O
ticagrelor	B:C1999375
during	O
<	O
12	O
months	O
.	O

